Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Completed · Not applicable
Conditions studied: Substance Withdrawal Syndrome
In brief
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain, diarrhea, nausea, and vomiting. Currently, the standard treatment for opioid withdrawal is clonidine (an alpha-2 adrenergic agonist), as well as supportive cares (anti-emetics, intravenous fluids). Olanzapine is an atypical antipsychotic that is given frequently in the ED for many of the same symptoms that are seen in patients who are experiencing opioid withdrawal, however its use in this toxidrome has never been studied. The hypothesis of this study is that olanzapine is a safe and efficacious option when compared to clonidine for the treatment of opioid withdrawal in the emergency department.
Key facts
- Study ID
- NCT02643355
- Run by
- Hennepin Healthcare Research Institute
- People needed
- 70
- Starts
- 2015-11-01
- Expected to finish
- 2017-06-21
- Last updated by the study team
- 2019-07-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Any patients who present to the emergency department where the providers are concerned for opioid withdrawal contributing to their symptoms on presentation is eligible for inclusion.
You may not qualify if…
- Age less than 18
- Allergy to either medication (olanzapine, clonidine)
- Inability to give informed consent
- Known pregnancy
Where it is running
- Hennepin County Medical Center — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.